Orexigen Empatic That Results For Second Obesity Drug Will Help Lure Partner
This article was originally published in Pharmaceutical Approvals Monthly
Given the potential to cause birth defects, Orexigen's obesity drug Empatic is probably not suited for the masses. Still, executives say the promising combo pill could complement the company's better known obesity agent Contrave and help bring a partner on board
You may also be interested in...
Vivus Obesity Pill Scores With Phase III Data, But Still Faces Major Market Hurdles
Qnexa combines two generics, but Vivus Chief Operating Officer Peter Tam says: "We are not concerned about generic substitution."
Orexigen Starts Partnership Talks On Obesity Drug Contrave
Firm stresses Phase III efficacy results will pass muster with FDA.
Sanofi Withdraws Zimulti NDA For Weight Loss
Company cites confusion over concerns raised by the Endocrinologic and Metabolic Drugs Advisory Committee, which voted against approval June 13.